Theravance Biopharma Files 8-K on Financials

Ticker: TBPH · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1583107

Theravance Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form Type8-K
Filed DateNov 10, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Theravance Biopharma dropped an 8-K on Nov 10, 2025, detailing financial results. Check it out.

AI Summary

Theravance Biopharma, Inc. filed an 8-K on November 10, 2025, to report on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in the Cayman Islands and its principal executive offices are located in South San Francisco, California.

Why It Matters

This 8-K filing provides an update on Theravance Biopharma's financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or immediate risks.

Key Players & Entities

  • Theravance Biopharma, Inc. (company) — Registrant
  • November 10, 2025 (date) — Date of earliest event reported
  • Cayman Islands (location) — State or Other Jurisdiction of Incorporation
  • South San Francisco, CA (location) — Principal executive offices
  • 650-808-6000 (phone_number) — Business phone number

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.

When was this 8-K filed?

This 8-K was filed on November 10, 2025.

Where is Theravance Biopharma, Inc. incorporated?

Theravance Biopharma, Inc. is incorporated in the Cayman Islands.

What is the primary business address for Theravance Biopharma, Inc.?

The principal executive offices are located at C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA 94080.

What is the Commission File Number for Theravance Biopharma, Inc.?

The Commission File Number is 001-36033.

Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-11-10 16:11:07

Key Financial Figures

  • $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 10, 2025 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-36033 98-1226628 (State or Other Jurisdiction of (Commission File Number) (I.R.S. Employer Identification Incorporation) Number) C/O Theravance Biopharma US, LLC 901 Gateway Boulevard South San Francisco , CA 94080 ( 650 ) 808-6000 (Addresses, including zip code, and telephone numbers, including area code, of principal executive offices) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02. Results of Operations and Financial Condition. On November 10, 2025, Theravance Biopharma, Inc. (the "Company") issued a press release and is holding a conference call regarding its financial results for the quarter ended September 30, 2025, and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report. The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated November 10, 2025 99.2 Slide deck entitled Third Quarter 2025 Financial Results and Business Update 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: November 10, 2025 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.